Morgan Stanley’s MAIA Biotechnology MAIA Stock Holding History

Morgan Stanley’s Portfolio MAIA Stock Details MAIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.4K	Buy	13,859 +12,859	+1,286%	+$23.7K	﹤0.01%	6740
2025 Q4	$1.53K	Buy	1,000 +168	+20%	+$219	﹤0.01%	7294
2025 Q3	$1.28K	Sell	832 -4,263	-84%	-$6.96K	﹤0.01%	7371
2025 Q2	$9.17K	Hold	5,095	–	–	﹤0.01%	6875
2025 Q1	$7.79K	Hold	5,095	–	–	﹤0.01%	6876
2024 Q4	$10.1K	Hold	5,095	–	–	﹤0.01%	6795
2024 Q3	$14.3K	Hold	5,095	–	–	﹤0.01%	6608
2024 Q2	$17.4K	Sell	5,095 -5,000	-50%	-$15.8K	﹤0.01%	6511
2024 Q1	$22.2K	Sell	10,095 -95	-0.9%	-$143	﹤0.01%	6459
2023 Q4	$11.9K	Buy	10,190 +5,095	+100%	+$8.22K	﹤0.01%	6792
2023 Q3	$11.2K	Buy	+5,095	New	+$10.1K	﹤0.01%	6694

Other funds holding MAIA

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

CWM

Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley's MAIA Position: Q1 2026 in Review

Morgan Stanley increased its MAIA Biotechnology (MAIA) stake by 1,286% in Q1 2026, buying an estimated $23.7K and bringing the position to 13,859 shares worth $19.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6740.

Morgan Stanley first reported a position in MAIA in Q3 2023 and has held it in 11 quarters since. The position peaked at $22.2K in Q1 2024. 33 funds tracked by Wall St. Rank hold MAIA as of Q1 2026.

Morgan Stanley held 13,859 shares of MAIA Biotechnology worth $19.4K as of Q1 2026.
Morgan Stanley bought 12,859 MAIA Biotechnology shares in Q1 2026, an estimated $23.7K.
MAIA Biotechnology made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6740 holding.
Morgan Stanley first reported a position in MAIA Biotechnology in Q3 2023 and has held it in 11 quarters since.
Morgan Stanley's MAIA Biotechnology position peaked at $22.2K in Q1 2024.
33 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.